The effect of supplemental beam radiation on prostate brachytherapy-related morbidity: Morbidity outcomes from two prospective randomized multicenter trials

International Journal of Radiation Oncology Biology Physics

Volumn 55, Issue 5, 2003, Pages 1288-1293

  Ghaly, Maged ^a   Wallner, Kent ^b,c   Merrick, Gregory ^e   True, Lawrence ^d   Sutlief, Steven ^b,c   Cavanagh, William ^b   Butler, Wayne ^e  

^a NEW YORK METHODIST HOSPITAL   (United States)

^b DEPARTMENT OF VETERANS AFFAIRS   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e WHEELING HOSPITAL   (United States)

Author keywords

Brachytherapy; Prostatic carcinoma

Indexed keywords

ANTIGENS; DOSIMETRY; RADIATION; UROLOGY;

BRACHYTHERAPY;

ONCOLOGY;

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; IODINE 125; PALLADIUM 103; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BEAM THERAPY; BRACHYTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FOLLOW UP; HIGH RISK POPULATION; HUMAN; IMPLANTATION; LOW ENERGY RADIATION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTICENTER STUDY; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE CANCER; QUESTIONNAIRE; RADIATION DOSE; RADIATION SICKNESS; RANDOMIZED CONTROLLED TRIAL; RECTUM; RECTUM DISEASE; SCORING SYSTEM; SEMINAL VESICLE; TREATMENT PLANNING; URINARY TRACT OBSTRUCTION;

EID: 0037376124     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(02)04527-3     Document Type: Article

References (22)

1. Nag S.N., Beyer D., Friedland J., et al. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys. 44:1999;789-799.
2. Mate T.P., Gottesman J.E., Hatton J., et al. High dose-rate after-loading iridium-192 prostate brachytherapy Feasibility report. Int J Radiat Oncol Biol Phys. 41:1998;525-533.
3. Martinez A.A., Kestin L.L., Stromberg J.S., et al. Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer The William Beaumont Phase II dose-escalating trial. Int J Radiat Oncol Biol Phys. 47:2000;343-352.
4. Syed A.M., Puthawala A., Austin P., et al. Temporary iridium-192 implant in the management of carcinoma of the prostate. Cancer. 69:1992;2515-2524.
5. Wallner K., Blasko J., Dattoli M. Supplemental beam radiation. Dattoli M. Prostate brachytherapy made complicated. 2nd ed:2001;11.11-11.23 SmartMedicine Press, Seattle.
6. Gelblum D.Y., Potters L., Ashley R., et al. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. Int J Radiat Oncol Biol Phys. 45:1999;59-67.
7. Krupski T., Petroni G.R., Bissonette E.A., et al. Quality-of-life comparison of radical prostatectomy and interstitial brachytherapy in the treatment of clinically localized prostate cancer. Urology. 55:2000;736-742.
8. Brandeis J.M., Litwin M.S., Burnison C.M., et al. Quality of life outcomes after brachytherapy for early stage prostate cancer. J Urol. 163:2000;851-857.
9. Merrick G.S., Butler W.M., Lief J.H., et al. Temporal resolution of urinary morbidity following prostate brachytherapy. Int J Radiat Oncol Biol Phys. 47:2000;121-128.
10. Wallner K., Merrick G., True L., et al. I-125 versus Pd-103 for low risk prostate cancer. Morbidity outcomes from a prospective randomized multicenter trial. Ca J Sci Am. 8:2002;67-73.
11. Merrick G.S., Butler W.M. Modified uniform seed loading for prostate brachytherapy Rationale, design, and evaluation. Techniques in Urology. 6:2000;78-84.
12. Han B., Wallner K., Aggarwal S., et al. Treatment margins for prostate brachytherapy. Semin Urol Oncol. 18:2000;137-141.
13. Barry M.J., Fowler F.J., O'Leary M.P., et al. The American Urologic Association symptom index for benign prostatic hyperplasia. J Urol. 148:1992;1549.
14. Cha C.M., Potters L., Ashley R., et al. Isotope selection for patients undergoing prostate brachytherapy. Int J Radiat Oncol Biol Phys. 45:1999;391-395.
15. Zeitlin S.I., Sherman J., Raboy A., et al. High dose combination radiotherapy for the treatment of localized prostate cancer. J Urol. 160:1998;91-96.
16. Iversen P., Nielsen L., Bak M., et al. Ultrasonically guided 125Iodine seed implantation with external radiation in management of localized prostatic carcinoma. Urology. 34:1989;181-186.
17. Howard A., Wallner K., Han B., et al. Clinical course and dosimetry of rectal fistulas after prostate brachytherapy. J Brachyther Int. 17:2001;37-42.
18. Theodorescu D., Gillenwater J.Y., Koutrouvelis P.G. Prostatourethral-rectal fistula after prostate brachytherapy Incidence and risk factor. Cancer. 89:2000;2085-2091.
19. Jackson A., Skwarchuk M.W., Zelefsky M.J., et al. Late rectal bleeding after conformal radiotherapy of prostate cancer (II) Volume effects and dose-volume histograms. Int J Radiat Oncol Biol Phys. 49:2001;685-698.
20. Shipley W.U., Zietman A.L., Hanks G.E., et al. Treatment related sequelae following external beam radiation for prostate cancer A review with an update in patients with Stages T1 and T2 tumor. J Urol. 152:1994;1799-1805.
21. Merrick G, Bulter W, Wallner K, et al. Long-term urinary morbidity after prostate brachytherapy. Int J Radiat Oncol Biol Phys. In press.
22. Merrick G.W., Butler W.M., Wallner K.E., et al. Prophylactic versus therapeutic alpha blockers following permanent prostate brachytherapy. Urology. 60:2002;650-655.